Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting the most appropriate therapy. The primary goal of treatment is to improve the quality of sleep with minimal next-day side effects. While generics are entrenched in the treatment algorithm, the branded dual orexin receptor antagonists Belsomra (Merck), Dayvigo (Eisai), and Quviviq (Idorsia) provide a new mechanism of action for patients in later lines of therapy. Additional agents in this class are progressing through the pipeline or are poised to launch in the U.S. market. Therefore, understanding the use of current therapies among newly diagnosed and recently treated insomnia patients is essential for optimizing the uptake of branded therapies.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed insomnia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed insomnia patients?
- How have Belsomra, Dayvigo, and Quviviq been integrated into the treatment algorithm, and what is their source of business?
- What percentage of insomnia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of insomnia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Content highlights
Real-world data: Patient-level claims data analysis
Key drugs covered: Belsomra, Dayvigo, Quviviq, zolpidem, eszopiclone, trazodone, zaleplon, quetiapine, benzodiazepines.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
